Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : BB's from the Gang at -- Ignore unavailable to you. Want to Upgrade?

To: Patricia Meaney who wrote (3924)	5/10/2010 10:53:12 PM
From: RikRichter	Read Replies (1) \| Respond to of 4066

PLBI 0.007 - Adult stem cell news: Today's significant PR NEWS for RNL BIO has positive implications for PLBI/Regenobody affiliation: RNL Bio Opens Special Clinic for Stem Cell Therapy in Japan 2010-05-10 01:26:06 RNL Bio, a Seoul-based biotech firm, opens its Japanese branch ‘Kyoto Bedesta Clinic’ on Friday, a world’s first special hospital using the adult stem cell in treatment for those who suffer from cancer and autoimmune disease. The clinic in Kyoto is expected to provide the medical service by tapping into RNL’s cutting-edge technology in cultivating stem cells in massive scale, thanks to the flexibility in Japanese government’s policy on advanced technology. S. Korea’s leading biotech company explained that it is meaningful to establish such a hospital with the Korea's medical technology onto Japan, the country well-known for its advanced level in medicine. Autoimmune diseases arise from an overactive immune response of the body against substances and tissues normally present in the body. In other words, the body actually attacks its own cells. “Kyoto Bedesta Clinic is going to fully utilize the RNL Bio’s stem cell therapy which has been proven to be secured and effective,” said an official from RNL Bio. RNL Bio uses stem cells taken from one’s own fat tissues. After the stem cells have been isolated, the cell expansion process takes a minimal amount of stem cells and copies them identically until there are millions and even billions. These stem cells, the patient’s own, are then injected back into them for various degenerative diseases such as arthritis, cardiovascular disease and spinal cord injury. “Kyoto is the Japan’s largest tourism city with 1,000 visitors annually and it is going to lead the medical-tourism market by combining the cutting-edge technology in medical field with the city image as the luxury tourism city,” said the official,” said the official. “Since the patients with autoimmune disease have little difficulty in movement, they hardly need to be hospitalized. Therefore, the synergy effect can be maximized by offering tourism service during the stem cell therapy for about a month.” kirimi99@ajnews.co.kr [???? ajnews.co.kr] ???? ????